PureTech Health (PRTC) Stock Price, News & Analysis

Company Overview

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $17.83 to $19.17
• 50-Day Range: $13.48 to $19.78
• 52-Week Range: $13.30 to $32.98
• Volume: 1,376 shs
• Average Volume: 4,708 shs
• Market Capitalization: $437.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.00
• Consensus Rating: Strong Buy

PureTech Health Stock Analysis - MarketRank™

PureTech Health scored higher than 42% of companies evaluated by MarketBeat, and ranked 621st out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

PureTech Health has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

PureTech Health has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PureTech Health are expected to decrease in the coming year, from ($4.34) to ($5.16) per share.

Price to Book Value per Share Ratio

PureTech Health has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the outstanding shares of PureTech Health have been sold short.

Short Interest Ratio / Days to Cover

PureTech Health has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PureTech Health has recently decreased by 4.59%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PureTech Health does not currently pay a dividend.

Dividend Growth

PureTech Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.04% of the outstanding shares of PureTech Health have been sold short.

Short Interest Ratio / Days to Cover

PureTech Health has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PureTech Health has recently decreased by 4.59%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

PureTech Health has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for PureTech Health this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added PureTech Health to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PureTech Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.30% of the stock of PureTech Health is held by insiders.

Percentage Held by Institutions

Only 0.04% of the stock of PureTech Health is held by institutions.

PRTC Stock Analysis - Frequently Asked Questions

How have PRTC shares performed this year?

PureTech Health's stock was trading at $18.46 at the beginning of 2025. Since then, PRTC shares have decreased by 1.4% and is now trading at $18.20.
View the best growth stocks for 2025 here.

Who are PureTech Health's major shareholders?

PureTech Health's top institutional investors include Pentwater Capital Management LP (0.14%).

How do I buy shares of PureTech Health?

Shares of PRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PureTech Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PureTech Health investors own include boohoo group (BOO), Cytokinetics (CYTK), Insmed (INSM), Super Micro Computer (SMCI), Arch Capital Group (ACGL), Adobe (ADBE) and Analog Devices (ADI).

Company Calendar

• Today: 5/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRTC
• CIK: 1782999
• Web: www.puretechhealth.com
• Phone: 617-482-2333
• Fax: 617-482-3337
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $45.00
• High Stock Price Target: $45.00
• Low Stock Price Target: $45.00
• Potential Upside/Downside: +147.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.68
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $4.32 million
• Price / Sales: 101.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.94 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 24,019,000
• Free Float: 22,673,000
• Market Cap: $437.15 million
• Optionable: Not Optionable
• Beta: 1.14